Skip to main navigation Skip to search Skip to main content

A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer

  • G. Galffy
  • , I. Lugowska
  • , E. V. Poddubskaya
  • , B. C. Cho
  • , M. J. Ahn
  • , J. Y. Han
  • , W. C. Su
  • , R. J. Hauke
  • , S. H. Dyar
  • , D. H. Lee
  • , P. Serwatowski
  • , D. L. Estelles
  • , V. R. Holden
  • , Y. J. Kim
  • , V. Vladimirov
  • , Z. Horvath
  • , A. Ghose
  • , A. Goldman
  • , A. di Pietro
  • , J. Wang
    • D. A. Murphy, A. Alhadab, M. Laskov
  • Pulmonology Hospital Törökbálint
  • Maria Sklodowska-Curie Institute of Oncology
  • VitaMed LLC
  • Yonsei University
  • National Cancer Center Korea
  • National Cheng Kung University
  • Nebraska Cancer Specialists
  • Saint Francis Hospital Cancer Center
  • University of Ulsan
  • Centrum Medyczne Dom Lekarski SA
  • Consorcio Hospitalario Provincial de Castellon
  • Oncology Hematology Associates
  • Seoul National University
  • GBUZ of Stavropol Territory Pyatigorsk Inter-regional Oncology Dispensary
  • Bacs-Kiskun Megyei Korhaz
  • Arizona Oncology Associates
  • Pfizer
  • Pfizer
  • LLC University Clinic of Headache

Research output: Contribution to journal › Article › peer-review

8   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Immunology and Microbiology